Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16), Briefing.com reports. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. During the same quarter last year, the firm earned ($0.29) EPS. The company’s quarterly revenue was up 168.0% compared to the same quarter last year.

Novavax (NVAX) traded down 1.1616% during trading on Thursday, reaching $0.9785. 4,242,607 shares of the company were exchanged. Novavax has a 1-year low of $0.73 and a 1-year high of $8.49. The stock’s market capitalization is $283.68 million. The company’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.15.

ILLEGAL ACTIVITY NOTICE: “Novavax, Inc. (NVAX) Releases Quarterly Earnings Results” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/novavax-inc-nvax-releases-quarterly-earnings-results.html.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price target on shares of Novavax in a report on Friday, July 21st. BidaskClub cut shares of Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $1.50 price target on shares of Novavax in a report on Wednesday, July 26th. Finally, Chardan Capital reaffirmed a “neutral” rating and issued a $1.50 price target on shares of Novavax in a report on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $5.61.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Earnings History for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.